Sort
10,766 grants matching “checkpoint inhibitor”
Metnase, PIKK, and RPA Roles in DNA Damage and Replication Stress Responses
$270,360Jac A Nickoloff · Colorado State University · R01 · FY2014 · GM
Control of Mitotic Entry by Regulators of Cdc2
$270,270Sally A Kornbluth · Duke University · R01 · FY2010 · GM
Project 3: HHLA2 as a THerapeutic Target in RCC
$270,115David McDermott · Beth Israel Deaconess Medical Center · P50 · FY2020 · CA
The Role of DRP-1 and Mitochondrial Fission in Pulmonary Arterial Hypertension
$270,000Stephen L Archer · Queen'S University At Kingston · R01 · FY2013 · HL
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
$270,000Amarnath Natarajan · University Of Texas Med Br Galveston · R01 · FY2008 · CA
The Role of DRP-1 and Mitochondrial Fission in Pulmonary Arterial Hypertension
$270,000Stephen L Archer · Queen'S University At Kingston · R01 · FY2016 · HL
Quantitative High Throughput Screening for Small Molecules Targeting CD47 in Cancer
$269,998Thomas W Miller · Institut Jean Paoli & Irene Calmettes Centre Regional De Lutte Contre Le Cancer · U01 · FY2021 · CA
Quantitative High Throughput Screening for Small Molecules Targeting CD47 in Cancer
$269,998Thomas W Miller · Institut Jean Paoli & Irene Calmettes Centre Regional De Lutte Contre Le Cancer · U01 · FY2020 · CA
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12
$269,895Arul M Chinnaiyan · University Of Michigan At Ann Arbor · P50 · FY2020 · CA
HTLV-I Tax activates the anaphase promoting complex
$269,894Chou-Zen Giam · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2014 · CA
Mechanisms of resistance to immune therapy in NSCLC
$269,874Qingsheng Li · University Of Louisville · P20 · FY2022 · GM
Project 1: New epigenetic therapy targets
$269,821Jean-Pierre J Issa · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA
Project 1: New epigenetic therapy targets
$269,820Jean-Pierre J Issa · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Project 1: New epigenetic therapy targets
$269,820Jean-Pierre J Issa · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA
Biomarker Identification to Increase Adjunctive Cryoablation and Checkpoint-Inhibitor Immunotherapy Response
$269,684Eric Wehrenberg-Klee · Massachusetts General Hospital · K08 · FY2020 · CA
Biomarker Identification to Increase Adjunctive Cryoablation and Checkpoint-Inhibitor Immunotherapy Response
$269,684Eric Wehrenberg-Klee · Massachusetts General Hospital · K08 · FY2021 · CA
Biomarker Identification to Increase Adjunctive Cryoablation and Checkpoint-Inhibitor Immunotherapy Response
$269,684Eric Wehrenberg-Klee · Massachusetts General Hospital · K08 · FY2024 · CA
Biomarker Identification to Increase Adjunctive Cryoablation and Checkpoint-Inhibitor Immunotherapy Response
$269,684Eric Wehrenberg-Klee · Massachusetts General Hospital · K08 · FY2022 · CA
Biomarker Identification to Increase Adjunctive Cryoablation and Checkpoint-Inhibitor Immunotherapy Response
$269,684Eric Wehrenberg-Klee · Massachusetts General Hospital · K08 · FY2023 · CA
Regulation of Genomic Instability in Early Breast Cancer
$269,670University Of California San Francisco · R01 · FY2005 · CA
Regulation of Genomic Instability in Early Breast Cancer
$269,670University Of California San Francisco · R01 · FY2004 · CA
Cancer Pharmacology
$269,566Xiaofeng Steven Zheng · Rutgers Biomedical And Health Sciences · P30 · FY2025 · CA
Genomic Instability and Cancer Genetics
$269,566Chang S Chan · Rutgers Biomedical And Health Sciences · P30 · FY2025 · CA
Clinical Investigation and Precision Therapy
$269,566Shridar Ganesan · Rutgers Biomedical And Health Sciences · P30 · FY2025 · CA
Regulation of Genomic Instability in Early Breast Cancer
$269,522University Of California San Francisco · R01 · FY2003 · CA